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ABSTRACT 
 Rationale  
Several studies have demonstrated a benefit of azithromycin for reversing or halting the FEV1-decline in 
post-lung transplant bronchiolitis obliterans syndrome (BOS). However, all but one were small, had a 
short follow-up and did not perform survival analysis.  
 Objectives 
To investigate the effects of long-term azithromycin on FEV1 and survival in transplant recipients with 
established BOS and to identify the variables associated with treatment response and outcome.  
 Methods and Measurements 
A retrospective, observational study in a large single-center cohort of 107 lung transplant recipients 
initiated on azithromycin for BOS was performed. Response was defined by a subsequent increase in 
FEV1 of ≥10% and survival curves were analyzed using the log-rank test. Cox regression analysis was 
performed to identify predictors for disease progression or outcome.  
 Results  
Azithromycin improved FEV1 in 43 recipients (40%), of which at the end of follow-up (mean 3.1±1.9 
years after start of azithromycin), 14 (33%) had relapsed and redeveloped BOS. In the initial 64 non-
responders (60%), FEV1 stabilized in 14 patients (22%), whereas in the remaining 50 (78%) FEV1 
further declined. Airway neutrophilia was significantly increased in responders compared to non-
responders (p=0.0003). Responders had a better overall survival compared to non-responders (p=0.05), 
however, the worst outcome was seen in initial responders who relapsed and in non-responders with 
disease progression. Multivariate analysis confirmed azithromycin-response to be an independent 
predictor for a better outcome, i.e. no progression/relapse (p<0.0001) or death/retransplantation 
(p=0.004), following BOS. 
 Conclusions  
Long-term azithromycin therapy benefits pulmonary function and survival in specific subsets of LTx 
recipients with established BOS.  
Abstract word count: 245              Key words: Azithromycin, Bronchiolitis Obliterans Syndrome, pulmonary function, survival 
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INTRODUCTION 
 Lung transplantation (LTx) has emerged as a suitable treatment option for selected patients with end-
stage lung disease. Despite improved survival rates, the mean actuarial 5-year survival rate is only 50%, 
increasing to about 70% in some high volume centres. [1,2] This is, however, far behind other solid 
organ transplantations. The major causal factor for this worse outcome is the development of chronic 
allograft dysfunction or Bronchiolitis Obliterans Syndrome (BOS), which has a 5-years prevalence of 
about 44%. [1] Several potential risk factors for the development of BOS have been identified, both 
immunologic (e.g. acute rejection, lymphocytic bronchiolitis, Human Leukocyte Antigen (HLA) 
mismatches) and non-immunologic factors (e.g. donor/recipient age, primary graft dysfunction, 
transplantation for primary pulmonary hypertension and cytomegalovirus (CMV) or community-
acquired respiratory virus infections). [3,4] New (non-immunologic) risk factors such as airway 
colonisation with Gram-negative bacteria (particularly Pseudomonas species) and gastroesophageal 
reflux have only just been identified. [5;6]  
 Until recently, treatment of BOS, mainly augmenting or changing immunosuppressive therapy, was 
most often unsuccessful and could at best result in a temporary arrest of the relentless decline in FEV1. 
[7] However, with the introduction of the neo-macrolide antibiotic azithromycin (AZI) in LTx it has 
become clear that this drug was not only able to arrest the FEV1 decline, but could even improve 
pulmonary function in about 35% of patients with established BOS, particularly in those with an 
increased broncho-alveolar lavage (BAL) neutrophilia. [8,9] Extensive research has unraveled some of 
the potential mechanisms by which AZI could interact with the pathophysiological mechanisms in BOS. 
Besides anti-inflammatory [9-12] and anti-oxidative [10] properties, it was also shown to reduce 
gastroesophageal reflux and aspiration after LTx [13] and, at least in cystic fibrosis, attenuate the 
detrimental effects of pseudomonal airway biofilm formation and colonisation. [14,15] Several centers 
have hitherto confirmed the presence of an ‘AZI responsive’ phenotype in BOS, however, all in small 
case series with a relatively short follow-up of 12 to 40 weeks. [9,16-20] Nevertheless, these findings in 
fact challenge the current definition of BOS, which is defined by an irreversible decline in FEV1. Only 
one long-term study, with a median follow-up of 1.3 years after initiation of AZI, in a larger cohort of 81 
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lung LTx recipients with BOS has been published to date. [12] In this cohort, 30% of the patients 
showed improvement in pulmonary function (FEV1 ≥10% predicted) after 6 months of therapy 
(‘responders’), of which 88% could already be identified after 3 months. Interestingly, responders also 
had higher pretreatment BAL neutrophil counts and demonstrated better survival after 6 months. 
Recently, the effect of long-term clarithromycin treatment was reported in a smaller cohort of 31 LTx 
recipients with BOS, of which 39 % responded regarding FEV1-evolution after 6 months. Likewise, this 
response in FEV1 was already present in 83% after 3 months and sustained up to 12 months of follow-
up. [21] 
 The aims of the current study were first of all to evaluate the effects of long-term AZI therapy 
regarding evolution of pulmonary function and overall survival in our LTx cohort. Our next aim was to 
identify possible risk factors associated with treatment response and better outcome after LTx. 
 
MATERIALS AND METHODS 
Study design and population  
 For the current study all LTx procedures performed from 07-1991 to 01-2009 in our center were 
retrospectively evaluated. Patients included in a randomized placebo-controlled trial with AZI (AZI001, 
inclusion from 07-2005 to 11-2007, n=83) were excluded for the current study. In case of 
retransplantation, evolution in time after each LTx procedure was taken into account for outcome 
analysis. Included patients were classified based on AZI-use (shorter vs. longer than 3 months). Patients 
who received long-term (>3 months) AZI therapy for BOS were further evaluated concerning airway 
inflammation, potential risk factors, evolution in pulmonary function and overall survival. The study was 
approved by the local University Hospital Ethical Review Board and all patients gave written informed 
consent. 
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Bronchoscopy with BAL and/or TBB 
Bronchoscopic procedures, for microbiological and virological assessment, quantification of cell 
differentials and protein levels and/or histology, were performed as previously described. [5,9] Briefly, 
BAL was routinely performed around fixed time points after LTx (21 days, 3, 6, 12, 18, 24, 30 months, 
3, 4, 5 years), or if AR, infection or BOS was suspected. Likewise, TBB was routinely performed at days 
21 and 90 post-LTx, thereafter in case of suspected acute rejection (AR), infection or BOS.  
Assessment of pulmonary function, allograft dysfunction (BOS) and mortality 
Spirometry was performed in agreement with American Thoracic Society (ATS)-criteria, prior to 
bronchoscopy (Masterscreen, Jaeger, Hoechberg, Germany). [22] BOS was diagnosed and staged 
according to the The International Society for Heart and Lung Transplantation (ISHLT) working 
formulation. [23] Response to AZI was defined as an increase in FEV1 ≥10% predicted after 3 to 6 
months of treatment (compared to FEV1 at start of AZI) and non-responders were defined as having an 
increase of <10%. At the end of follow-up, sustained response was defined as FEV1 ≥110%, stabilization 
as a FEV1 between 90-110% and disease progression or relapse as FEV1<90% of FEV1 (% predicted) at 
start of AZI. 
Survival data were obtained using mortality information in the local University Hospital transplant 
database, in which all patients transplanted since 1991 are registered.  
Immunosuppressive and prophylactic regimen 
Conventional post-operative immunosuppressive and prophylactic treatment has been previously 
described. [5, online supplementary] Concisely, all LTx recipients received triple-drug 
immunosuppressive therapy with methylprednisolone, cyclosporine A (CsA) or tacrolimus (FK) and 
azathioprine (AZA) or mycophenolate mofetil (MMF). AR grade >A1 was treated with intravenous 
pulse doses of methylprednisolone for 3 days, tapered to the oral maintenance dose over the next 2-3 
weeks, while A1 rejection was treated with augmenting oral steroids, similarly followed by tapering. 
Additionally, in case of recurrent AR, conversion from CsA to FK or from AZA to MMF was 
performed based on a case-by-case decision. There was no strict protocol for treatment of isolated grade 
B rejection. Chronic allograft rejection (BOS stage ≥0-p) was additionally treated with AZI (250mg qd 
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5 days followed by 250mg qd thrice weekly) and in case of BOS-progression with conversion of 
immunosuppressives or, less frequently, switching to rapamycin, total lymph node irradiation or 
retransplantation. None of our patients received photopheresis treatment for BOS. 
Initial infectious prophylaxis consisted of gancyclovir or acyclovir for CMV (depending on donor 
and receptor CMV status), inhaled amphotericin B for Aspergillus and long-term prophylaxis of 
sulfamethoxazole-trimethoprim for Pneumocystis. Antibiotic treatment for bacterial infection after LTx 
was guided using bacteriologic cultures; airway colonisation, however, was not treated by antibiotics, 
except in pre-operatively colonized Cystic Fibrosis (CF) patients, in whom post-operatively 
prophylactic therapy with colistin nebulisation was continued for 2-3 months. All patients received a 
prophylactic H2-receptor antagonist or a low dose proton pump inhibitor (20 mg omeprazole qd or 
equivalent) if gastroesophageal reflux disease (GERD) had been diagnosed before LTx. If reflux was 
diagnosed after LTx, the H2-receptor antagonist was switched to a high dose proton pump inhibitor or 
the dose of the latter was augmented (40 mg omeprazole qd or equivalent). Fundoplication surgery after 
LTx was only performed once in one of our LTx recipients until present. GERD was assessed either 
with pH-impedance measurement or by gastroscopy.  
Statistical analysis 
Using Graphpad Prism 4.0 (San Diego, CA, USA), Wilcoxon signed rank test, unpaired t-test, 
Mann-Whitney-U test and One-Way Analysis of Variance test (ANOVA; Kruskall-Wallis with non-
parametric Dunn’s post-testing) were performed where appropriate. Contingency tables were analyzed 
using Chi square test and Kaplan-Meier survival curves with the log-rank test. Cox proportional hazard 
survival regression analysis (p<0.05 entry and p>0.05 removal criteria) was used to estimate hazard 
ratios of clinically relevant variables predicting disease progression (i.e. either progression/relapse of 
FEV1-decline or retransplantation/death after initiation of AZI) and their 95% confidence intervals. 
Results of the data are presented either as total values, mean±standard deviation, median (inter-quartile 
range) or as percentages. A p-value of <0.05 was considered significant.  
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RESULTS 
Study population  
 After exclusion of the patients in the AZI001-trial (n=83), 369 LTx recipients with 380 LTx 
procedures (of all 448 recipients with 463 procedures since 07-1991) were included in the current study 
(Figure 1). Patients’ characteristics are summarized in table 1.  
 Long-term macrolide therapy after LTx was used in 43.2% (n=164/380 LTx) and 56.8 % of all LTx 
recipients never received macrolides (n=216/380 LTx) (Figure 1). In the patients ever treated with 
macrolides, AZI was initiated for BOS in 65.8% (n=108/164), of which one patient was excluded for 
further analyses as subsequent FEV1-evolution after AZI could not be assessed because of a follow-up 
<3 months due to death. Macrolides were used for other reasons than BOS in 34.1% (n=56/164), more 
specifically because of recurrent infections (n=23/56) or shortly after AR because of insufficient FEV1-
recovery (n=21/56; started at 9.7±8.5 days post-AR), as well as prophylactically to prevent BOS 
(n=9/56) or for GERD (n=3/56). In the latter group, subsequent FEV1-evolution after AZI was not 
evaluated for the current study, moreover in 19.6% of these patients (n=11/56) FEV1 could not be 
evaluated due to intercurrent bronchial suture problems (e.g. stenosis, stenting) or development of 
malignancies.  
 Generally, long-term AZI therapy for BOS (n=107) was well-tolerated and few adverse events were 
noted, which were in fact mainly gastro-intestinal complaints (nausea, dyspepsia or colitis) necessitating 
temporary halting or stopping treatment in 5/107 patients. No potentially life-threatening arrhythmias or 
drug-interactions were observed.  
 
Freedom from BOS 
 Time to BOS was not statistically different between the BOS-cohorts never treated (n=46) or treated 
with AZI (n=107) (Table 1). In the BOS-cohort initiated on AZI (n=107), we identified 43 (40%) 
responders and 64 (60%) non-responders based on the subsequent evolution in FEV1 (Figure 1, Table1). 
AZI was initiated in BOS stage 0p in 8/107 patients, 5 patients in the responder and 3 in the non-
responder group, whereas all others were initiated in BOS stage ≥1. Time to BOS was not statistically 
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different between responders and non-responders, although the latter seemed to develop BOS somewhat 
later, which may explain why AZI tended to be started somewhat later in non-responders as well as why 
the duration of AZI-treatment generally was longer in responders (Table 1).  
 Evolution in FEV1 over time in the different groups is summarized in figures 2+3 and in table 3. In 
29 (67%) of the patients who initially responded to AZI, FEV1-recovery was sustained at the end of 
follow-up, whereas 14 (33%) later relapsed and redeveloped BOS after a median of 620 (300-1101) days 
after AZI was initiated. In the initial non-responders, FEV1 stabilized in a minority of the patients (n=14 
or 22%), whereas in the majority (n=50 or 78%) FEV1 further declined over time. During follow-up, 7 
patients were retransplanted for BOS after a median of 539 (214-1124) days post-LTx, 6 of which were 
initial non-responders and 1 a responder to AZI who later relapsed (p=0.148)(Table 3).  
 In general, post-operative time to BOS ≥1 inversely correlated with BAL neutrophilia at the time of 
BOS-diagnosis/start of AZI (r=-0.25, p=0.021), as well as with donor age (r=-0.22, p=0.028) and tended 
to be inversely related with ischemic time (r=-0.18, p=0.073) and pseudomonal colonisation (r=-0.17, 
p=0.081). Furthermore, BAL neutrophilia at the start of AZI therapy significantly correlated with 
subsequent response in FEV1 (r=0.24, p=0.024) and was significantly increased in responders compared 
to non-responders: 29.3 (9.3-69.7) vs. 11.5 (2.9-43.8) % (p=0.025) (Figure 4). No significant differences 
in neutrophilia could be demonstrated, however, between both sustained responders and those patients 
who later relapsed/redeveloped BOS, or between patients in whom FEV1 stabilized and those in whom 
FEV1 further declined after initiation of AZI (Figure 4). Responders demonstrated a significant decrease 
in BAL neutrophilia 3 to 6 months after initiation of AZI (median 4.2 (1.8-17.6) %, p=0.041), which was 
absent in non-responders. This significant decrease in BAL neutrophilia after initiation of AZI was both 
observed in patients with a sustained response and those who later relapsed (p= 0.050 and p= 0.006 
respectively) (Figure 4). Patients who initially responded but later relapsed despite AZI, had a 
significantly lower BAL neutrophilia at the time of relapse compared to their neutrophilia at the time of 
initial response: 9.6 (5.2-24.8) vs. 34.0 (15.0-82.2) % (p=0.023). Besides BAL neutrophilia, other factors 
were associated (or tended to be) with FEV1-response after AZI in univariate analysis, such as mean and 
highest PGD-score in the first 48 hours post-LTx (r=0.23, p=0.033 and r=0.22, p=0.038 respectively), 
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cumulative incidence of CMV-pneumonitis (r= -018, 0.057), CMV-mismatch (r=0.17, p=0.076) and 
post-operative time to start of AZI (r= -0.16, p=0.097) (Table 2). However, neither pseudomonal airway 
colonisation, nor the presence of GERD were associated with response (p=0.485 and p=0.259 
respectively).  
 
Overall survival 
 The BOS-cohort treated with AZI (n=107) had a significantly better overall survival compared to the 
one never treated with AZI (n=46) (p<0.0001) (Figure 5A). Moreover, responders had a significantly 
better overall survival compared to non-responders (p=0.05) (Figure 5A, Table 3). Cause of death is 
summarized in table 3. Besides response to AZI (r=-0.29, p=0.028), other factors were associated (or 
tended to be) with mortality in univariate analysis: post-operative time to BOS (r=0.72, p<0.0001), 
duration of AZI treatment (r= -0.31, p=0.001), cumulative incidence of acute rejections (r=-0.42, 
p=0.028), double-sided LTx (r= -0.19, p=0.049) and receptor age (r=0.17, p=0.074) (Table 2). When 
comparing the 4 subgroups, overall survival was significantly better in those patients who had a 
sustained response compared to those who later relapsed/redeveloped BOS (p=0.010), as well in those 
patients in whom FEV1 stabilized compared to those in whom it further progressed (p=0.016). 
Moreover, overall survival was similar in patients with a sustained response in FEV1 compared to those 
in whom FEV1 stabilized (p=0.788), as well as in those who later relapsed compared to those in whom 
FEV1 further declined after initiation of AZI (p=0.739) (Figure 5B). As expected, patients with a 
sustained response had a much better overall survival compared to those in whom FEV1 had further 
declined after initiation of AZI (p=0.001), however, patients in whom FEV1 had stabilized also 
unexpectedly demonstrated a better overall survival compared to those who initially responded but later 
relapsed (p=0.038) (Figure 5B). Kaplan-Meier survival curves illustrating freedom from mortality or 
retransplantation after the diagnosis of BOS ≥1 in the former subgroups were additionally summarized 
in the online data supplement (Figure E1 A+B). 
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Risk factors for disease progression/relapse or outcome (death/retransplantation) following BOS 
 Multivariate Cox regression analysis identified initial response to AZI and early initiation of AZI as 
important protective factors for subsequent disease progression or relapse during follow-up (Table 4). Of 
all other clinically relevant variables, only a higher cumulative incidence of preceding CMV 
pneumonitis significantly increased the risk for progression/relapse whereas preceding lymphocytic 
bronchiolitis as well as a higher PGD-score (both increased in responders compared to non-responders) 
were associated with a significantly lower risk for further disease progression/relapse following 
initiation of AZI for BOS (Table 4).  
 Similarly, early initiation of AZI, initial response to AZI and duration of AZI treatment, besides the 
presence of GERD and earlier onset of BOS proved to be protective regarding death or retransplantation 
following BOS (Table 4). 
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DISCUSSION 
 The current cohort-study, which is the largest and has the longest follow-up after AZI thus far (mean 
3.1±1.9 years), demonstrates long-term AZI therapy to significantly improve pulmonary function in 
about 40% of the LTx recipients with established BOS. No severe adverse events were noted with long-
term AZI therapy. The current data confirm previous reports from small observational or prospective 
case-series [10,16-20] and retrospective cohort-studies of long-term AZI [8] or clarithromycin [21] 
treatment for BOS. Furthermore, it corroborates the recently described dichotomy within BOS. [24] 
However, almost 33% of responders later redeveloped BOS (despite AZI therapy and without concurrent 
BAL neutrophilia), which is in accordance with the data of the Hannover group in which 33% of initial 
responders later redeveloped a decreasing FEV1. [8] On the other hand, in about 20% of the non-
responders FEV1 stabilized during follow-up, which proved to be beneficial for longer survival. Initial 
responders to AZI had higher pretreatment BAL neutrophilia, as well as higher post-LTx PGD scores 
and tended to have a higher cumulative incidence of lymphocytic bronchiolitis episodes, whereas non-
responders had a higher cumulative incidence of preceding CMV-pneumonitis. No significant 
differences in clinical risk factors could be demonstrated when comparing patients with a sustained 
response to those who later relapsed or patients with FEV1 stabilization to those with disease 
progression. Responders had a significantly better overall survival compared to non-responders, again in 
accordance with previous data. [8] Moreover, we could demonstrate remarkably similar survival in 
patients either with a sustained response compared to those in whom FEV1 stabilized, as well as in 
patients who later relapsed during AZI therapy compared to those with disease progression. Multivariate 
analysis confirmed response to AZI to be an independent predictor for a better outcome (i.e. no disease 
progression/relapse or death/retransplantation) following BOS. In brief, the current findings not only 
indicate that long-term AZI treatment is safe, but more importantly show that it can significantly 
improve pulmonary function and reduce mortality in specific subsets of LTx recipients.   
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 Our current data corroborate the previously postulated dichotomy in the clinical spectrum of BOS by 
our group, more specifically differentiating neutrophilic reversible allograft dysfunction (NRAD; early 
post-LTx onset, AZI-responsive) from fibroproliferative BOS (fBOS; later post-LTx onset, not AZI-
responsive).[24] The presence of BAL neutrophilia is another important discriminating 
characteristic.[24] Moreover, a previous study by our group revealed some interesting findings from a 
pathophysiological point of view as it demonstrated that AZI could significantly reduce BAL 
neutrophilia and IL-8 mRNA levels in patients with established BOS.[9] Post-hoc analysis showed that 
particularly the responders demonstrated an increased neutrophilia and IL-8 compared to non-
responders, which in fact already pointed towards a possible dichotomy within BOS.[9,24] Nowadays, 
the beneficial effects of AZI in LTx are believed to be at least partially attributable to their anti-
inflammatory properties, including direct and indirect antibacterial activity, modulation of systemic and 
pulmonary cytokine profiles (IL-6, IL-8, TNF-α) and an inhibitory effect on key cells of the innate 
immune system, such as macrophages and neutrophils. [25] In the current study, initial responders to 
AZI not only had higher pretreatment BAL neutrophilia compared to non-responders, but also had a 
higher post-LTx PGD score and a somewhat higher cumulative incidence of lymphocytic bronchiolitis 
episodes, which may account for triggering neutrophilic airway inflammation in these patients. Airway 
colonisation and reflux, on the contrary, were unexpectedly not different between both groups. In non-
responders (fBOS), on the other hand, other mechanisms than airway neutrophilia may be involved in 
the onset of BOS [26,27], which might later on also play a role in patients who relapse after an initial 
response to AZI since they afterwards do not demonstrate an increased airway neutrophilia anymore. 
These patients may benefit from total lymph-node irradiation (TLI) which has been shown to decrease 
the FEV1 decline in the AZI non-responsive BOS phenotype [28]. However, the intercurrent pathways 
and mechanisms in this phenotype currently remain elusive and need further investigation.  
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 The current data nevertheless strongly suggest that evaluation of BAL neutrophilia should be part of 
daily practice when diagnosing a patient with BOS and that AZI should be started as soon as possible, 
besides usual therapeutic interventions commonly used in each center such as optimizing 
immunosuppressive treatment. Although initial improvement in FEV1 can be mainly expected in LTx 
recipients with increased (i.e. >15-20%) BAL neutrophilia [8,9], we have demonstrated that FEV1 may 
nevertheless stabilize in some patients with low BAL neutrophilia and that this stabilization is associated 
with a better outcome, comparable to that of patients with a sustained response. However, although these 
promising data suggest that association of AZI may be beneficial in some patients with low or normal 
BAL neutrophilia at the onset of BOS, it is unclear whether this stabilization is really due to AZI 
treatment or represents a spontaneous evolution in BOS. Contrasting the above-mentioned differences 
between responders and non-responders, we could, not observe significant differences in clinical risk 
factors between further subgroups of patients when comparing patients with a sustained response in 
FEV1 to those who later relapse on the one hand, or those in whom FEV1 stabilizes to those with disease 
progression on the other hand. Thus, predicting whether a responder will later relapse or a non-responder 
will either stabilize or progress after initiation of AZI currently remains impossible. Yet, as patients with 
disease progression or who relapse despite AZI seem to have the worst outcome; other treatment options 
should be considered as soon as possible during their course of FEV1-decline. For the latter patients, 
salvage therapy with TLI [28], extracorporeal photopheresis [29] or retransplantation could be 
implemented in selected cases.  
 
 Inevitable limitations to the current study are inherent to its retrospective design and patient-
selection criteria. Nevertheless, both sample size (n=107) and follow-up time (median of almost 6 years 
and followed outcomes for up to 17.6 years post-LTx) can actually be regarded as quite considerable in 
view of the average LTx center-volume, the prevalence of BOS and overall post-LTx survival world-
wide. We also note that there were no major changes in diagnostic criteria or chronic 
immunosuppressant regimen in the studied cohort treated with AZI, yet we cannot fully exclude a 
possible era-effect since transplantations from the early 1990’s on were included for analyses. This can 
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also explain why the ‘never AZI for BOS’-cohort has somewhat different patient characteristics (e.g. 
proportionally more single-sided LTx), which could bias survival analysis in this group. Next, the 
presence of GERD was neither uniformly assessed (either by pH-impedance measurement or by 
gastroscopy), nor assessed at a fixed time-point after LTx (i.e. early vs. late after LTx or pre- vs. post-
AZI), which could bias the observed prevalence of post-LTx GERD and might explain why no 
differences were seen between responders vs. non-responders, opposed to the observation made by the 
Hannover group who demonstrated a higher prevalence of proton-pump inhibitor-use and GERD-
symptoms in the responder group. [8] Finally, pseudomonal airway colonisation, which has previously 
been associated with neutrophilic airway inflammation [30] and the development of BOS [5,31,32], only 
tended to be inversely related with time to onset of BOS ≥1. Furthermore, a similar prevalence was 
noted in responders and non-responders in the current study, which can therefore not explain the 
observed differences in BAL neutrophilia, treatment response or outcome between both groups.   
 
 In conclusion, our study confirms that long-term AZI is safe and benefits pulmonary function and 
survival in a specific subset of LTx recipients with established BOS, particularly in those with increased 
airway neutrophilia. Some 33% of patients initially responding to AZI may nevertheless redevelop BOS, 
which is associated with worse outcome. As even in non-neutrophilic BOS AZI treatment may stabilize 
FEV1, AZI should probably be offered to every patient diagnosed with BOS. Meticulous follow-up 
should be implemented to detect patients in whom there is a further decline in FEV1 or in whom FEV1 
again declines after an initial response. In these patients appropriate action should be undertaken to 
implement other treatment options.  
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WHAT THIS STUDY ADDS TO THE FIELD 
Scientific Knowledge on the Subject: Azithromycin (AZI) has been shown to reverse the FEV1-decline 
in post-lung transplant bronchiolitis obliterans syndrome (BOS). One study also demonstrated a survival 
benefit after 6 months of treatment.  
What This Study Adds to the Field: The current cohort-study, which is the largest and has the longest 
follow-up after AZI thus far, confirms that long-term AZI therapy can significantly improve pulmonary 
function in 40% of LTx recipients with established BOS, of which 33% may nevertheless later redevelop 
BOS. Responders had a better overall survival compared to non-responders; however, the worst outcome 
was seen in initial responders who relapsed and in non-responders with disease progression. Multivariate 
analysis confirmed response to AZI to be an independent predictor for a better outcome (no disease 
progression/relapse or death/retransplantation) following BOS. 
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FIGURE LEGENDS 
Figure 1 
Flow chart of our lung transplant cohort, subdivided according to long-term macrolide-use. 
Abbreviations: LTx: lung transplantation, AZI: azithromycin, AR: acute cellular rejection, BOS: 
bronchiolitis obliterans syndrome, NRAD: neutrophilic reversible allograft dysfunction, fBOS: 
fibroproliferative BOS, FEV1: forced expiratory volume in one second, FU: follow-up, GERD: 
gastroesophageal reflux disease.  
Notes: in the historic BOS-cohort not treated with AZI, BOS subtypes were classified according to time 
of onset and course of FEV1 decline (i.e. NRAD: early post-LTx onset, slowly declining FEV1 vs. fBOS: 
late post-LTx onset, rapid declining FEV1). Because neither BAL neutrophilia at onset of BOS, nor 
response to AZI could be assessed, subtypes were given the suffix ‘-like’.  
 
Figure 2 
Evolution in FEV1 (% predicted) over time respectively before (Best: best post-LTx FEV1), at the start of 
azithromycin (AZI) and after 3 months (AZI +3m), 6 months (AZI +6m) and at the end of follow-up 
(End FU; AZI +mean time(±standard deviation) since start AZI in years) in the entire cohort initiated on 
azithromycin (A: AZI for BOS, n=107) and the different subgroups (based on the response in FEV1 
following AZI-treatment): Responders (B, n=43) and Non-responders (C, n=64). Dots present median 
and bars the interquartile range. P-values (vs. FEV1 at start of AZI) were calculated using the Wilcoxon 
signed rank test and are expressed as *: p<0.05, **: p<0.01 and ***: p<0.001. Percentages below graphs 
represent mean change (±standard deviation) in FEV1 respectively between best post-LTx FEV1 and 
FEV1 at start of AZI, or between FEV1 at start of AZI and FEV1 after 3 months, 6 months and at the end 
of follow-up. 
 
Figure 3 
Evolution in FEV1 (% predicted) over time respectively before (Best: best post-LTx FEV1), at the start of 
azithromycin (AZI) and after 3 months (AZI +3m), 6 months (AZI +6m) and at the end of follow-up 
(End FU; AZI +mean time (±standard deviation) since start AZI in years) in patients with either a 
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sustained response in FEV1 (n=29) (A) or who later relapsed/redeveloped BOS (n=14) on one hand (B) 
and in patients in whom FEV1 stabilized (n=14) (C) or FEV1 further declined/progressed (n=50) on the 
other hand (D). Dots present median and bars the interquartile range. P-values (vs. FEV1 at start of AZI) 
were calculated using the Wilcoxon signed rank test and are expressed as *: p<0.05, **: p<0.01 and ***: 
p<0.001. Percentages below graphs represent mean change (±standard deviation) in FEV1 respectively 
between best post-LTx FEV1 and FEV1 at start of AZI, or between FEV1 at start of AZI and FEV1 after 3 
months, 6 months and at the end of follow-up. 
 
Figure 4 
Box-and-whisker plots (median±range) of broncho-alveolar lavage (BAL) neutrophilia (%) at the 
diagnosis of BOS respectively at the start of azithromycin (Start AZI) and after 3 to 6 months of AZI-
treatment (AZI+3-6m) in Responders (n=43) and Non-responders (=64) (A) and their different 
subgroups (B). P-values were calculated using the Wilcoxon signed rank test or Mann-whiney U test and 
are expressed as *: p<0.05 and **: p<0.01. 
 
Figure 5 
Kaplan-Meier survival curves for actuarial overall survival after lung transplantation (LTx). P-values 
were calculated using the log-rank test and are expressed as *: p<0.05, **: p<0.01 and ***: p<0.001. 
Vertical tick-marks represent censored events. Lines represent either the BOS-cohort not treated with 
azithromycin (Never AZI for BOS, n=46), the BOS-cohort initiated on azithromycin (AZI for BOS, 
n=107) and the different subgroups (based on the response in FEV1 following AZI-treatment): 
Responders (n=43) and Non-responders (n=64) (A), each of which subdivided respectively in patients 
with a sustained response (n=29) or who later relapsed/redeveloped BOS (n=14) on one hand and in 
patients in whom FEV1 stabilized (n=14) or FEV1 further declined/progressed (n=50) on the other hand 
(B).  
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TABLES 
Table 1: Included patients’ characteristics 
 
Total group 
(n=380) 
Never AZI for BOS cohort 
(n=46) 
AZI for BOS cohort 
(n=107) 
Responders 
(n=43) 
Non-responders 
(n=64) 
p-value 
 
Age at LTx, years 50 (39-57) 51 (42-57) 51 (37-57) 52 (41-59) 50 (31-56) 0.74 
§
 
Male/Female, n (%) 215/165 (57/43) 27/19 (59/41) 58/49 (54/46) 23/20 (53/47) 35/29 (55/45) 0.98 ^ 
Type of LTx, n (%)      0.08 ^ 
   SSLTx 220 (58) 14 (30) 59 (55) 26 (60) 33 (52)  
   SLTxx 119 (31) 25 (53) 35 (33) 13 (30) 22 (34)  
   HLTx 41 (11) 7 (15) 13 (12) 4 (10) 9 (14)  
Underlying disease, n (%)      0.97 ^ 
   Emphysema (COPD) 139 (37) 22 (48) 42 (39) 21 (49) 21 (33)  
   Pulmonary Fibrosis 80 (21) 11 (24) 18 (17) 5 (12) 13 (20)  
   Cystic Fibrosis 47 (12) 2 (4) 12 (11) 6 (14) 6 (9)  
   Pulmonary Arterial Hypertension 34 (9) 4 (9) 9 (8) 5 (12) 4 (6)  
   α1-antitrypsin deficiency 26 (7) 2 (4) 7 (7) 3 (7) 4 (6)  
   Eisenmenger syndrome 21 (6) 2 (4) 7 (7) 2 (5) 5 (8)  
   Obliterative bronchiolitis 17 (4) 1 (2) 7 (7) 1 (2) 6 (9)  
   Bronchiectasis 9 (2) 1 (2) 3 (3) 0 3 (5)  
   Miscellaneous 7 (2) 1 (2) 2 (2) 0 2 (3)  
Time LTx to BOS 0p, days 532 (256-11199) 499 (207-1008) 595 (282-1298) 500 (173-1328) 732 (331-1293) 0.32 
§
 
Time LTx to BOS ≥1, days  754 (349-1543) 630 (314-1040) 817 (364-1764) 655 (319-1519) 1014 (451-1803) 0.28 
§
 
Time LTx to AZI treatment, days 
 503 (150-1309) NA 768 (273-1709) 685 (225-1328) 1060 (444-1866) ° 0.007 
§
 
Duration of AZI treatment, days 592 (266-1463) NA 612 (269-1476) 1142 (327-1760) * 561 (241-1148) 0.08 
§
 
Time LTx to post-operative death, days 523 (73-1209) 1141 (584-2141) 1470 (896-2179) 1319 (885-2011) 1647 (841-2582) <0.0001 
§
 
Time of follow-up, years 3.3 (1.0-6.1) 2.9 (1.4-6.4) 5.9 (3.3-8.2) ** 5.9 (4.0-8.2) 5.8 (3.2-8.1) <0.0001 
§
 
 
Table legend 
Patients’ characteristics for all evaluated patients (n=380 LTx), the cohort never treated (n=46) or treated with azithromycin (AZI) for BOS (n=107) and the 
Responder (n=43) and Non-responder (n=64) subgroups (see also flow chart in Figure 1). Data are presented as median (interquartile range) or as total value 
(percentage). Footnotes: 
§
 non-parametric Kruskall-Wallis test (all groups: total group vs. Never AZI for BOS vs. AZI for BOS cohort vs. Responders vs. Non-
responders), ^ Chi-square test (all groups), ° 0.05<p<0.1 and * p<0.05 Mann Whitney U-test (Never AZI for BOS vs. AZI for BOS cohort; Responders vs. Non-
responders). Abbreviations: LTx: lung transplantation (SS: sequential single, S: single, H: heart-), COPD: chronic obstructive pulmonary disease, BOS: bronchiolitis 
obliterans syndrome, NA: not applicable. 
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Table 2: Risk factors in azithromycin responders and non-responders 
 
AZI for BOS cohort 
(n=107) 
Responders 
(n=43) 
Non-responders 
(n=64) 
Sustained 
(n=29) 
Relapse 
(n=14) 
Stabilization 
(n=14) 
Progression 
(n=50) 
p-value 
 
SS/HLTx, n (%) 72 (67) 30 (71) 42 (66) 22 (76) 8 (57) 11 (79) 31 (62) 0.38 ^ 
Recipient age at LTx, years 51 (37-57) 52 (41-59) 50 (31-56) 52 (41-59) 51 (33-60) 51 (31-57) 49 (30-57) 0.74 
§
 
Donor age at LTx, years 39 (22-49) 41 (25-52) 35 (21-48) 41 (26-54) 42 (22-52) 36 (19-52) 35 (21-48) 0.71 
§
 
CMV mismatch, n (%) 51 (48) 25 (58) ° 26 (41) 20 (69) 5 (36) 6 (43) 20 (40) 0.06 ^ 
Ischemic time, minutes 333±104 321±89 340±114 328±96 308±75 340±128 340±111 0.90 
§
 
PGD score T0-T48          
   Mean  1.70±0.71 1.87±0.15 
*
 1.57±0.10 2.00±0.62 ° 1.58±0.67 1.25±0.46 1.63±0.76 0.03 
§
 
   Highest  2.29±0.80 2.49±0.12 
*
 2.14±0.12 2.63±0.63 ° 2.17±0.83 1.75±0.89 2.21±0.80 0.03 
§
 
A rejection score, cum. incid. 0.78±1.00 0.74±1.09 0.80±0.95 0.69±1.10 0.86±1.09 0.43±0.51 0.90±1.02 ° 0.39 
§
 
B rejection score, cum. incid. 0.34±0.70 0.49±0.94 ° 0.23±0.46 0.34±0.61 0.79±1.37 0.36±0.50 0.20±0.45 0.19 
§
 
CMV pneumonitis, cum. incid. 0.20±0.44 0.09±0.29 0.27±0.51 
*
 0.10±0.31 0.07±0.27 0.43±0.65 0.22±0.46 0.13 
§
 
Non-CMV pneumonitis, cum. incid. 1.1±1.6 1.3±2.2 0.88±1.1 1.52±2.59 1.00±1.11 0.50±0.94 0.98±1.17 0.37 
§
 
P. aeruginosa colonisation, n (%)         
   Colonized at BOS≥0p 25 (23) 10 (23) 15 (23) 6 (21) 4 (29) 4 (29) 11 (22) 0.89 ^ 
   Colonized during follow-up 34 (31) 12 (28) 22 (34) 8 (28) 4 (29) 4 (29) 18 (36) 0.85 ^ 
Gastroesophageal reflux, n (%)  42 (39) 20 (47) 22 (34) 12 (41) 8 (57) 3 (21) 19 (38) 0.28 ^ 
Immunosuppressive therapy         
   FK-based CNI-regimen, n (%) 65 (61) 27 (63) 38 (59) 17 (59) 10 (71) 9 (64) 31 (62) 0.87 ^ 
   AZA-based CCI-regimen, n (%) 70 (65) 29 (67) 41 (64) 20 (69) 9 (64) 7 (50) 32 (64) 0.50 ^ 
 
Table legend 
Risk factors in the cohort treated with azithromycin (AZI) for BOS (n=107), the Responders (n=43) and Non-responders (n=64) and the different subgroups according to 
subsequent FEV1-evolution: sustained response (n=29), relapse of BOS (n=14), stabilization (n=14) or further progression of FEV1-decline (n=50). Data are presented as 
median (interquartile range), mean±standard deviation or as total value (percentage).  
Footnotes: ° 0.05<p<0.1 and * p<0.05 with Mann Whitney U-test for non-parametric, unpaired t-test for parametric continuous variables respectively or Chi-square test for 
categorical variables (Responders vs. Non-Responders, Sustained vs. Relapse, Stabilization vs. Progression), 
§ 
non-parametric Kruskall-Wallis test (4 subgroups: Sustained 
vs. Relapse vs. Stabilization vs. Progression), ^ Chi-square test (4 subgroups: Sustained vs. Relapse vs. Stabilization vs. Progression).  
Abbreviations: LTx: lung transplantation (SS: sequential single, H: heart-), CMV: cytomegalovirus, PGD: primary graft dysfunction, T0: immediately post-LTx, T48: 48 
hours post-LTx, cum. incid.: cumulative incidence, FK: tacrolimus, AZA: azathioprine, CNI: calcineurin-inhibitor, CCI: cell-cycle inhibitor, BOS: bronchiolitis obliterans 
syndrome.   
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Definitions: PGD was assessed at 0, 12, 24 and 48 hours after LTx, mean score was calculated for each patient using PGD-score at every time-point during the 48 hour 
interval post-LTx. Non-CMV pneumonitis was defined as a bacterial or fungal pulmonary infection requiring in-hospital treatment with antibiotics or anti-fungal drugs; 
CMV pneumonitis was defined as biopsy-proven pulmonary CMV infection. P. aeruginosa airway colonisation was assessed by evaluating all respiratory specimens by 
standardized cultured techniques as previously described. [5] Gastroesophageal reflux was assessed by standardized gastroscopy or pH-impedance measurement. 
Immunosuppressive therapy was assessed at 3-9 months after LTx. 
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Table 3: Evolution in FEV1 and outcome in azithromycin responders and non-responders 
 
AZI for BOS cohort 
(n=107) 
Responders 
(n=43) 
Non-responders 
(n=64) 
Sustained 
(n=29) 
Relapse 
(n=14) 
Stabilization 
(n=14) 
Progression 
(n=50) 
p-value 
 
FEV1 best post-LTx, L / %pred                                    2.31 (1.74-3.16) 
81 (64-104) 
2.36 (1.89-2.95) 
86 (69-105) 
2.31 (1.66-3.26) 
78 (63-104) 
2.31 (1.89-2.82) 
83 (69-98) 
2.69 (1.82-3.95) 
93 (68-115) 
3.0 (1.89-3.62) 
103 (73-115) 
2.16 (1.59 (3.26) 
76 (60-101) ° 
0.35 
§
 
0.18 
§
 
FEV1 start of AZI, L / %pred                                    1.77 (1.32-2.39)  
62 (47-77) 
1.82 (1.46-2.35)  
67 (50-81)  
1.68 (1.09-2.45)  
59 (46-74) ° 
1.77 (1.49-2.24) 
 66 (52-77) 
1.86 (1.46-3.12)  
74 (48-88) 
2.18 (1.58-2.82) 
74 (57-94) 
1.63 (1.05-2.33) ° 
56 (43-71) 
*
 
0.24 
§ 
0.03 
§
 
FEV1 AZI +3 mo., L / %pred                                    1.88 (1.31-2.62) 
65 (48-86) 
2.21 (1.67-2.83) 
78 (62-93) 
1.65 (1.06-2.32) 
**
 
55 (42-74) 
***
 
2.19 (1.61-2.68) 
76 (61-89) 
2.51 (1.75-3.59) 
90 (64-107) 
2.28 (1.51-2.69) 
76 (58-91) 
1.51 (1.03-2.23) 
*
 
51 (41-68) 
**
 
0.003 
§ 
<0.0001 
§ 
FEV1 AZI +6 mo., L / %pred                                    1.84 (1.19-2.58) 
64 (45-85) 
2.14 (1.71-2.88) 
81 (64-97) 
1.48 (0.96-2.25) 
***
 
50 (36.5-71) 
***
 
2.11 (1.79-2.71) 
74 (65-91) 
2.55 (1.59-3.57) 
92 (62-110) 
2.32 (1.56-2.98) 
78 (57-91) 
1.27 (0.92-2.07) 
**
 
45 (36-61) 
***
 
<0.0001 
§ 
<0.0001 
§ 
FEV1 end of follow-up, L / %pred                                              
1.46 (0.89-2.24)  
51 (35-79) 
1.81 (1.35-2.53)  
66 (51-90) 
1.07 (0.81-1.90) 
***
 
42 (28-59) 
***
 
2.08 (1.71-2.63) 
79 (63-91) 
1.23 (0.78-1.83) 
**
 
47 (29-63) 
**
 
2.28 (1.56-2.91) 
80 (50-96) 
0.97 (0.72-1.53) 
***
  
40 (25-49) 
***
 
<0.0001 
§ 
<0.0001 
§
 
 
         
Retransplantation, n (%) 7 (7) 1 (2) 6 (9) 0 1 (7) 0 6 (12) 0.14 ^ 
Mortality, n (%) 27 (25) 6 (14) 21 (33) 
*
 1 (3) 5 (36)
 *
 1 (7) 20 (40)
 *
 0.001 ^ 
Cause of death, n (%)        0.47 ^ 
   Chronic allograft dysfunction/BOS
 
13 (12) 3 (7) 10 (16) 0 3 (21)
 
 0 10 (20)  
   Malignancy 5 (5) 2 (5) 3 (5) 1 (3) 1 (7) 0 3 (6)  
   Infection 4 (4) 1 (2) 3 (5) 0 1 (7) 0 3 (6)  
   Cardiac arrest 1 (1 0 1 (2) 0 0 0 1 (2)  
   Haemorrhage 1 (1 0 1 (2) 0 0 0 1 (2)  
   Unknown 3 (3) 0 3 (5) 0 0 1 (7) 2 (4)  
         
Time of follow-up, years 5.9 (3.3-8.2) 5.9 (4.0-8.2) 5.8 (3.2-8.1) 6.8 (2.9-8.4) 5.3 (3.9-8.1) 6.9 (4.8-11.6) 5.7 (2.5-8.0) 0.16 
§
 
 
Table legend 
Evolution in FEV1 and outcome with follow-up time in the cohort treated with azithromycin (AZI) for BOS (n=107), the Responders (n=43) and Non-responders (n=64) and 
the different subgroups according to subsequent FEV1-evolution: sustained response (n=29), relapse of BOS (n=14), stabilization (n=14) or further progression of FEV1-
decline (n=50). Data are presented as median (interquartile range) or as total value (percentage).  
Footnotes: ° 0.05<p<0.1 and * p<0.05 with Mann Whitney U-test for non-parametric and unpaired t-test for parametric continuous variables respectively, Chi-square test for 
categorical variables (Responders vs. Non-responders, Sustained vs. Relapse, Stabilization vs. Progression), 
§ 
non-parametric Kruskall-Wallis test (4 subgroups: Sustained vs. 
Relapse vs. Stabilization vs. Progression), ^ Chi-square test (4 subgroups: Sustained vs. Relapse vs. Stabilization vs. Progression).  
Abbreviations: FEV1: Forced expiratory volume in one second (L: liters / %pred: % predicted), LTx: lung transplantation, mo.: months, BOS: bronchiolitis obliterans 
syndrome. 
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Table 4: Multivariate Cox regression analysis model for disease progression and outcome after initiation of azithromycin for BOS.  
Outcome Variable Hazard ratio 95% CI p-value 
Progression or relapse of FEV1-decline Response to AZI 0.12 0.05-0.28 <0.0001 
 Cumulative incidence of LB 0.39 0.20-0.77 0.006 
 PGD-score 0.62 0.39-0.97 0.037 
 Time to AZI  0.98 0.97-0.99 <0.0001 
 CMV pneumonitis 1.39 1.06-1.82 0.017 
Death or reTx Response to AZI 0.10 0.02-0.48 0.004 
 Gastroesophageal reflux 0.16 0.04-0.73 0.018 
 Time to onset of BOS≥1 0.95 0.92-0.97 <0.0001 
 Time to AZI  0.96 0.95-0.98 <0.0001 
 Duration of AZI 0.97 0.95-0.98 0.0001 
 
Table legend 
Multivariate Cox regression analysis model for disease progression and outcome (death or retransplantation; reTx) after initiation of azithromycin (AZI) for bronchiolitis 
obliterans syndrome (BOS). Variables included in the forward stepwise regression model included: time and duration of AZI treatment, response to AZI, time to onset of 
BOS≥1, broncho-alveolar  (BAL) neutrophilia (%) at diagnosis of BOS, receptor age, donor age, type of transplantation (single vs. double lung), cytomegalovirus (CMV)-
mismatch between donor and receptor, ischemic time, highest primary graft dysfunction (PGD)-score in the first 48 hours post-transplant, cumulative incidence of 
respectively acute rejections, lymphocytic bronchiolitis (LB), CMV and non-CMV pneumonitis episodes preceding BOS or end of follow-up, gastroesophageal reflux during 
follow-up and P. aeruginosa airway colonisation preceding BOS.  
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FIGURES 
Figure 1  
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Figure 2 
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Figure 3  
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Figure 4 
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Figure 5 
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Figure legend 
Kaplan-Meier survival curves illustrating freedom from mortality or retransplantation (reTx) after the 
diagnosis of BOS ≥1. Patients free of BOS and in BOS stage ≤0p were censored for analysis. P-values were 
calculated using the log-rank test and are expressed as *: p<0.05, **: p<0.01 and ***: p<0.001. Vertical tick-
marks represent censored events. Lines represent either the BOS-cohort not treated with azithromycin (Never 
AZI for BOS, n=46), the BOS-cohort initiated on azithromycin (AZI for BOS, n=107) and the different 
subgroups (based on the response in FEV1 following AZI-treatment): Responders (n=43) and Non-responders 
(n=64) (A), each of which subdivided respectively in patients with a sustained response (n=29) or who later 
relapsed/redeveloped BOS (n=14) on one hand and in patients in whom FEV1 stabilized (n=14) or FEV1 
further declined/progressed (n=50) on the other hand (B).  
